

H K E C L T S E H K L

w

w

w

温州 院

Wenzho



2.1 F D t I t s

2

3 B _ I E _ E IE A D _ K

I 2021, C ID-19 ()
F

, G
G
S
w
:

I 2021, G ' w
w
w
H
, G H
H
, K H
w
;

w
K H
K H
w
K H
B
H
w
w
;

H
w
H
C
, C
K
H
w
G
w
I
G
,

L C T H
30, 2021, N H
24), 25 (D 31, 2020:
H), I
8,328 (D 31, 2020: 7,483).

14 F - H C
I

2021, G
F , G
I
I -
S

G
T , G
, H
C H
H & C T
E

L , 14 F -  w
 -
 (支持浙江高質量發展建設共同富裕示範區) , I 
 C E M H S 14
 F S 
 w
 - . I G ,

411-8000 Cost 8000

T G w w : ()
 () w ; () ;
 () .

T w w :

F t s t s	
J 30,	
2021	2020
(MB'000)	(MB'000)
(t)	(t)
576,419	438,886
27,023	19,116
19,369	7,148
622,811	465,150

t s

w

w

G ,

. T , w , w
 G , w

w

:

F t s t s	
J 30,	
2021	2020
(MB'000)	(MB'000)
(t)	(t)

t t s s

C

G

t s s

C

G

s t s

C

G

D

MB576.4

w

G

H , C

2020,

K

H

H

C , K

H

C

H

, w

w

2020. D

, w

, w

w

G ,

w

37.6%

w

2020,

T		W	W	G	'	W	:

D 31.6% MB498.4 2020, 27.7%,
 : () G , - C K
 H , G H , C H , C , K H
 G , w 3.0%. T
 w 86.5% (
 J 30, 2020: 86.3%).

D 29.9% MB78.0 2020,
 w 41.3%. T
 w 13.5% (
 J 30, 2020: 13.7%).

D 32.7% 2020,
 77.7% w (26.8%
 J 30, 2020: 77.0%);
 w 2020, 22.3%
 w (J 30, 2020: 23.0%),
 w : 14.5% (J 30, 2020: 14.2%),
 71.9% (
 J 30, 2020: 78.8%).

C G , w
 ,
 w : w G , w . T

	F u t u r e s e s t i m a t e s a s o f J u n e 30,	
	2021 (in \$ B'000)	2020 (in MB'000)
EBITDA	149,254	112,156
Depreciation	146,561	110,048
Amortization	18,892	15,297
Goodwill impairment	39,899	37,019
Other non-recurring	24,513	18,390
Restructuring costs	13,396	11,647
	25,132	18,906
Cost of sales	417,647	323,463

D 4, G , w MB417.6 , 29.1% w 2020. I w : () 33.1% ; () 33.2% w ; () - 23.5% w 2020; () 7.8% w , 2020, w .

F , w 35.7% (J 3(88 345.7). T)-20 () TJ M70.1)0,

$$412G_{ss} - t - G_{ss} - t| \dots$$

D	$\frac{D}{G}$	G	MB
2020. 1	31.5%	w	168.7
2020. 2	37.6%	w	158.8

	Financial results Year ended June 30,	
	2021	2020
	(in millions)	(in millions)
Total revenue	34.1%	29.7%
Cost of sales	4.8%	14.9%
Gross profit	27.5%	26.3%
Operating expenses	21.3%	47.1%
Cost of sales, net of operating expenses	27.1%	27.6%

415A *st t v E, v s s*

D , ,

G

w , w ,
:

G . T

F t v s t s

J v 30,

2021 2020
(MB'000) (MB'000)
(t v) ()

E	42,156	35,136
D	8,632	5,970
C	2,845	2,406
T	1,226	1,468
	<u>18,076</u>	<u>9,659</u>

t st t v v, v s s

<u>72,935</u>	<u>54,639</u>
---------------	---------------

D , ,

G

MB72.9

, 33.5%
2020. D ,

w

w
J 30, 2020: 12.4%).

G w 12.7% (

416 *s v D v v, t E, v s s*

D , , G ,

MB11.8 (

J 30, 2020: MB2.6

), 347.6%

w

2020. T

w G w 2.0% (
2020: 0.6%), w w : ()

J 30,

G ; w ,
()

I

 K H .

4.1.7 Financial Results

		Financial Results	
		Year ended June 30,	
		2021	2020
		(in \$ B'000)	(in MB'000)
		(in million yen)	(in million yen)
Income Statement	Income	1,684	2,454
	Finance income	(23)	125
	Operating income	(11,674)	(9,165)
	Income before income taxes	(6,558)	(4,921)
	Income taxes	(548)	(339)
Income after income taxes		<u>(17,119)</u>	<u>(11,846)</u>

Differences between the consolidated financial statements and the financial statements of the parent company are as follows:

MB17.1, 2020, with MB5.3, 2020, with MB2.5, 2020, with MB1.6, 2020.

4.1.8 Investment Income

		Financial Results	
		Year ended June 30,	
		2021	2020
		(in \$ B'000)	(in MB'000)
		(in million yen)	(in million yen)
Investment Income	Investment income	(755)	(1,020)
	Finance income	6,119	96
	Income	<u>5,364</u>	<u>(924)</u>

D ☒ , MB5.4 ,
☒ G .

4.1.9 Capital Investment

D ☒ , MB12.0
 (J 30, 2020: MB16.1), 1.9%
 G , (J 30, 2020: 3.5%). A J
 30, 2021 D 31, 2020,
 G MB44.2 MB33.9 , ,
 10.6% 9.5%

4.1.10 - Investment (E, S)

- -
 T w w - , -
 :

	Footnotes	
	J 30,	
	2021	2020
	(B'000)	(MB'000)
	()	()
G	297	30
-	308	535
N -	605	565
D	(973)	(2,627)
-	(1,739)	(408)
N -	(2,712)	(3,035)

D MB0.6 , w ☒ w , - G
D MB2.7 , ☒ , - G
w 2020. MB1.7

4.1.1.1 I *ts* E *ts*

D ☒ , MB16.5 (57.3%
J 30, 2020: MB10.5),
w 2020. F ☒
J 30, 2020, w 28.7% 26.7%, .

4.2 F *ts*

4.2.1 I *ts*

A J 30, 2021, MB39.1 (D
31, 2020: MB37.5),
.

4.2.2 A *ts* *ts*

A J 30, 2021, 31 MB3 30, 320 C

4.24 Investment Assets

A J 30, 2021, G (D 31,
2020: MB107.8),
G , G (,
C J 24, 2021).

4.25 Investment Assets

A J 30, 2021, -
MB57.7 (D 31, 2020: MB57.4). D
MB0.3
J F G

4.26 Investment Assets

A J 30, 2021, - - MB276.5 (MB69.5
D 31, 2020: MB227.6),
w G
.

4.27 Investment Assets

A J 30, 2021, MB69.0 (MB69.5
D 31, 2020: MB69.6).

4.28 Investment Assets

A J 30, 2021, MB14.4 (D
31, 2020: MB13.0).

4.29 Investment Assets

A J 30, 2021, MB35.8 (D 31,
2020: MB76.6), MB23.3

4.4 Investments

4.4.1 Business

As at December 30, 2021, the Group's investment in MB564.6 (December 31, 2020: MB426.5), which is measured at MB144.9, is MB283.0.

4.4.2 Contract

As at December 30, 2021, the Group's contract is measured at MB426.5.

4.4.3 Assets

The Group's assets are measured at MB426.5.

4.4.4 Liabilities

The Group's liabilities are measured at MB426.5. As at December 30, 2021, the Group's liabilities are measured at MB426.5, which is measured at MB227.2.

4.4.5 Financial Instruments

The Group's financial instruments are measured at MB426.5, which is measured at MB227.2. The Group's financial instruments are measured at MB426.5, which is measured at MB227.2.

4.4.6 Exchange Rate

The Group's exchange rate is measured at MB426.5, which is measured at MB227.2. The Group's exchange rate is measured at MB426.5, which is measured at MB227.2. The Group's exchange rate is measured at MB426.5, which is measured at MB227.2.

4.4.7 Other

As at December 30, 2021, the Group's other investments are measured at MB426.5, which is measured at MB227.2. The Group's other investments are measured at MB426.5, which is measured at MB227.2.

6 B E E E E

I

—

,

11 F I A C I A 附註

11.1 A 附註

11.1.1 A 附註

本集團採用的會計政策符合《國際財務報告準則》（“**IFRS**”）及《香港會計準則》（“**HKAS**”）的要求，並符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求。本集團採用的會計政策符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求，並符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求。

本集團採用的會計政策符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求，並符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求。本集團採用的會計政策符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求，並符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求。

本集團採用的會計政策符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求，並符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求。本集團採用的會計政策符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求，並符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求。

本集團採用的會計政策符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求，並符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求。本集團採用的會計政策符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求，並符合《國際會計準則》（“**IAS**”）及《香港會計準則》（“**HKAS**”）的要求。

11.1.2 附註 C 附註

		Funds received July 30,	
		2021	2020
		(in thousands)	(in thousands)
4. Net assets		<u>41,143,150</u>	<u>28,901,235</u>
C			
N		41,143,150	28,901,235
N			
C	w		
N			
N	-	42,913,178	36,409,947
		(1,770,028)	(7,508,712)
5. Total assets		<u>41,143,150</u>	<u>28,901,235</u>
A			
A	-	42,913,178	36,409,947
		(1,770,028)	(7,508,712)
6. Expenses			
—B (MB)		0.59	0.50
—D (MB)		<u>0.59</u>	<u>0.50</u>

1122I t C s t t t F s t

A E	J t 30, 2021 (t)	D 31, 2020 (A)
C t ss ts		
C	296,970,557	206,499,564
F		
A	372,917,472	321,407,965
	57,506,857	63,435,813
A	17,297,814	11,927,882
I	39,076,028	37,508,471
t t ss ts	783,768,728	640,779,695
- t ss ts		
-	57,749,854	57,404,918
L -	122,971,948	93,726,511
I		107,804,936
F	669,724,131	533,743,384
C	12,609,215	134,941,286
- -	276,494,473	227,568,279
I	177,459,129	162,536,728
G w	84,959,992	71,605,598
L -	153,405,333	153,550,840
D	43,126,042	46,576,821
-	28,598,739	18,708,451
t - t ss ts	1,627,098,856	1,608,167,752
A A E	2,410,867,584	2,248,947,447

IAB I IE A D HA EH DE N E I		June 30, 2021 (Actual)	December 31, 2020 (Actual)
Current assets			
Cash		313,000,000	312,500,000
Accounts receivable		69,012,231	69,573,927
Contract assets		14,438,238	12,965,170
Prepaid expenses		32,991,649	42,785,133
Other current assets		24,678,538	49,046,555
Current assets		35,785,120	76,603,400
		64,262,900	35,540,617
		554,168,676	599,050,882
Non-current assets			
Long-term investments		232,400,000	110,992,970
Long-term receivables		227,210,276	189,801,284
Long-term assets			
Debt		9,493,579	9,645,475
Debt		15,498,566	25,032,439
		484,602,421	335,472,168
		1,038,771,097	934,523,050
Liabilities			
Current liabilities		74,600,300	74,600,300
Current liabilities		814,055,511	804,566,529
Long-term liabilities			(23,311,144)
Long-term liabilities		37,300,150	36,593,229
Long-term liabilities		361,603,198	319,396,941
		1,287,559,159	1,211,845,855
		84,537,328	102,578,542
		1,372,096,487	1,314,424,397
Total assets		2,410,867,584	2,248,947,447

1123I t₁ C s t₂ t t₃ ts C s F

	F t s t s J ₁ 30,	
	2021	2020
	(t)	(t)
1 C s s , t t ₁ s		
C	539,688,900	411,405,749
C	10,297,037	8,311,056
	<u>549,985,937</u>	<u>419,716,805</u>
-t t s s		
C	(218,754,957)	(174,912,876)
C	(207,867,279)	(162,022,960)
☒	(27,309,627)	(14,474,391)
C	(58,738,353)	(50,507,831)
	<u>(512,670,216)</u>	<u>(401,918,058)</u>
-t t s t s		
t s s , t t ₁ s	<u>37,315,721</u>	<u>17,798,747</u>
2 C s s st t ₁ s		
C		30,010,000
C		96,370
N		
	16,043,548	3,870,905
N	14,240,472	
C	<u>41,676,480</u>	
	<u>71,960,500</u>	<u>33,977,275</u>
-t t s s		
C	(83,456,941)	(67,075,009)
C	(30,000,000)	(15,145,000)
N	(16,771,568)	(25,593,510)
C	(2,650,000)	(2,600,000)
	<u>(132,878,509)</u>	<u>(110,413,519)</u>
-t t s s st t ₁ s	<u>(60,918,009)</u>	<u>(76,436,244)</u>

Financial statements as at June 30,	
2021	2020
(unaudited)	(audited)

3. Cash and cash equivalents

2,445,056

23,361,500



1124 Investments in Equity Securities

	Earnings (Losses) from Investments in Equity Securities						
	Cost	Unrealized Gains	Unrealized Losses	Dividends	Net Change	Net Income (Loss)	
Balance at January 1, 2021	<u>74,600,300</u>	<u>804,566,529</u>	<u>(23,311,144)</u>	<u>36,593,229</u>	<u>319,396,941</u>	<u>102,578,542</u>	<u>1,314,424,397</u>
Net Change	▲	▲	▲	▲	42,913,178	(1,770,028)	41,143,150
Cost	▲	2,445,056	(2,445,056)	▲	▲	▲	▲
Dividends	▲	5,512,658	▲	▲	▲	▲	5,512,658
Dividends	▲	▲	▲	▲	▲	(15,959,186)	(15,959,186)
	▲	▲	25,756,200	▲	▲	▲	25,756,200
	▲	1,531,268	▲	▲	▲	▲	1,531,268
Earnings	————▲	————▲	————▲	<u>706,921</u>	<u>(706,921)</u>	————▲	————▲
Net Change	————▲	————▲	————▲	————▲	————▲	<u>(312,000)</u>	<u>(312,000)</u>
Balance at June 30, 2021 (unaudited)	<u><u>74,600,300</u></u>	<u><u>814,055,511</u></u>	<u><u>————▲</u></u>	<u><u>37,300,150</u></u>	361,603,198	84,537,328	1,372,096,487

	E					N - T	
	5	C	T	5			
Balok J 1, 2020	<u>75,500,000</u>	<u>824,715,445</u>	<u>(21,721,144)</u>	<u>33,189,321</u>	<u>252,800,715</u>	<u>97,024,925</u>	<u>1,261,509,262</u>
N					36,409,947	(7,508,712)	28,901,235
C						21,771,500	21,771,500
5		3,914,851	(1,590,000)				2,324,851
T w		(2,253,553)				(1,709,223)	(3,962,776)
B			(14,506,364)				(14,506,364)
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u>18,385,531</u>	<u>18,385,531</u>
Balok J 30, 2020							
()	<u><u>75,500,000</u></u>	<u><u>826,376,743</u></u>	<u><u>(37,817,508)</u></u>	<u><u>33,189,321</u></u>	<u><u>289,210,662</u></u>	<u><u>127,964,021</u></u>	<u><u>1,314,423,239</u></u>

11.3.2 Assets

T

w :

J 30, 2021

D

31, 2020

3 3
3 6
6 1
1 2
2 3
3

J 30, 2021 D 31, 2020
() (A)

61,633,050	54,689,668
3,698,543	9,659,122
2,674,824	4,105,307
269,088	571,326
230,735	252,094
505,991	296,410
69,012,231	69,573,927

11.3.3 Assets

F t s t s J 30, 2021 2020
() ()

576,419,335	438,885,748
46,392,061	26,264,704
622,811,396	465,150,452
417,647,183	323,463,045
36,502,676	13,401,709
454,149,859	336,864,754

C
C

() F w J 13, 2018, C\$ 2,460,000 D \$

T

w:

For the years ended June 30,
2021 2020
(in thousands) (in thousands)

T

57,665,247 39,403,983

I

25%

14,416,312 9,850,996

T

I

25%

T

(686,539)

C

,

558,238

579,650

F

A

▲

121,674

(1,358,322)

(490,212)

D

w

w

3,592,408

440,640

I

16,522,097

10,502,748

11.36 Dividends

March 26, 2021,
Dividend

Balance
March 31, 2020. T

2020

w
C

June 18, 2021.

March 30, 2020,
Dividend

Balance
March 31, 2019. T

2019

w
C

June 18, 2020.

12 DEFINITION

A	C	B
B	H	B H C ., L . (北京怡寧醫院有限公司), C w , -w
A 17, 2015, w		
B		C
C K H	C K H C ., L . (蒼南康寧醫院有限公司), J 15, 2012, C w , w - w	
C K H H	C K H C ., L . (長春康林心理醫院有限公司), C w , F 16, 2016, C -w w	
C ' K H	C ' K H H C ., L . (淳安康寧黃鋒醫院有限公司), A 16, 2020, C w , -w w	
C K H	K H C ., L ., w C, H M B H K S E (C : 2120)	
CG C	C G C A 14 H K L	
D ()	() C	
D S ()	() C , w MB1.00 , w MB w	
G H	G H C ., L . (溫州怡寧老年醫院有限公司), N 2, 2015, w - C , w	
G w	C	

H\$ ()

()

MB1.00 , C M , w B H
K \$ E

HKD

w H K

H K

H K \$ A ☒ C

H K L

E G H K L , \$, T \$
w

H K \$ E

T \$ E H K L

J F

C J M & H I
E I F ☒ (L\$ L
☒) (重慶金浦醫療健康服務產業股權投資基金
合夥企業(有限合夥)),
☒ C M 22, 2016 w C , F
 , 3.5461%

L C H

D 11, 2020, ☒ C w , w -
w

L K H

L K H C ., L . (臨海康寧醫院有限公
司),
F 2, 2015, ☒ C w , -w
w

L C H

T L C H C ., L . (台州市路橋
慈寧醫院有限公司,
H C ., L . (台州市路橋怡寧醫院有限公司)),
☒ C w
D 12, 2016, C , -
w w

☒ K H

☒ K H C ., L . (平陽康寧醫院有
限公司),
N 2, 2015, ☒ C w ,
w - w

☒ H

☒ H H C ., L . (浦江怡寧
黃峰醫院有限公司),
w ☒ C
C , -w\$ w .

M

M \$ A ☒ C

☒ C C

☒ , C w , H K ,
M T w

K	H	K	H	C ., L . (青田康寧醫院有限公司), A 1, 2011, C w , w - w			
	H	H	C ., L . (衢州怡寧醫院有限公司), N 20, 2015, C , - w w				
			J 30, 2021				
MB		w	C				
§ ()	()	MB1.00 , D § ()	H § ()				
§ ()	()	§ ()					
		(C 622 w H K)					
T	K	H	T	K	H	C ., L . (台州康寧醫院有限公司), J 30, 2016, C w , -w w	
	N	H		N		H	C ., L . (溫嶺南方精神疾病專科醫院有限公司), 2018, C w , J 20, -w w
	C	H		C	H	C ., L . (溫州慈寧醫院有限公司), J 25, 2006, C w , -w w	
	G			G			

I H L . (怡寧心理互聯網醫院(溫州)有限公司),
 10, 2020, C w , M - w

K H K H C ., L . (永嘉康寧醫院有限公司),
 D 12, 2012, C w , w w

K H K H C ., L . (樂清康寧醫院有限公司),
 S 3, 2013, C w , w w

%

B B
 K H s t C , t
 G A
 C

A , C
 27, 2021

A , C , D M . G AN , M .
 ANG L M . ANG H ; D M . TANG
 M . IN H ; - D M . HA , M . H NG
 M . LI N .